Retatrutide is an investigational triple-agonist drug (targeting GLP-1, GIP, and glucagon receptors) developed by Eli Lilly for obesity and type 2 diabetes management. It’s still in clinical trials (Phase 3 as of late 2024) and not FDA-approved or commercially available in any dosage, including 40 mg. Here’s a breakdown based on available data:

Key Facts from Clinical Trials

• Doses Tested: Highest doses in trials like TRIUMPH (Phase 3) reach up to 12 mg weekly subcutaneous injection. A 40 mg dose far exceeds this and isn’t documented in any published studies—likely unsafe or untested.
• Efficacy (from Phase 2 trials, e.g., NEJM 2023):

• Mechanism: Mimics gut hormones to reduce appetite, slow gastric emptying, boost insulin, and increase energy expenditure via glucagon.
• Side Effects (common, dose-dependent): Nausea (up to 50% at high doses), vomiting, diarrhea, constipation. Rare: Pancreatitis, gallbladder issues, heart rate increase (~5-10 bpm).
• Status: Expected approval ~2026-2027 if trials succeed. Not available via prescription.

Warnings on 40 mg

• No Legitimate Source: Claims of “40 mg Retatrutide” online are almost certainly counterfeit, mislabeled research chemicals, or scams from unregulated sites (e.g., China-based vendors). These could contain impurities, incorrect peptides, or nothing at all.
• Risks of High/Unauthorized Doses:

• Real-world reports (e.g., Reddit, forums) of “high-dose” retatrutide often involve bunk product causing hospitalizations.

Legit Alternatives (Approved)

Advice: Do not buy or use unapproved Retatrutide—it’s illegal in most places without research authorization and poses serious health risks. Consult a doctor for obesity treatments. Trials recruit via clinicaltrials.gov (search “retatrutide”). Sources: Lilly press releases, NEJM publications, FDA trial database.